At the 2017 annual meeting of the American Liver Disease Association, a large observational study reported that the use of direct antiviral (DAA) therapy to eradicate hepatitis C virus (HCV) can reduce the risk of liver cancer by 71%. In patients with cirrhosis and non-cirrhosis, the risk of liver cancer is reduced. In the United States, most primary liver cancer occurs in people infected with HCV. Researchers at the University of Washington hypothesized that the eradication of HCV could eliminate or at least significantly reduce the risk of ailse ae. However, before HCV eradication, the patient may have developed cirrhosis or liver fibrosis. Even if HCV eradication may be too late, there is still a risk of developing liver cancer. In addition, recent studies suggest that the risk of liver cancer in HCV-infected patients who have received new DAA treatment is still increased. The researchers analyzed 62,051 patients with HCV infection who received 83,695 antiviral treatments. After 180 days of antiviral treatment, an average of 3,271 new liver cancers occurred during a follow-up of 6.1 years. Patients with cirrhosis who failed treatment had the highest incidence of liver cancer (3.25 / 100 person-years), followed by patients with cirrhosis who had sustained virological response (SVR) (1.97 / 100 person-years), and patients who had no cirrhosis but failed treatment (0.87 / 100 person-years) and patients without cirrhosis who obtained SVR (0.24 / 100 person-years). Multivariate analysis showed that after adjusting for potential confounders, SVR was significantly associated with a lower risk of liver cancer, regardless of whether DAA treatment (aHR = 0.29), DAA combined with interferon treatment (aHR = 0.48), or interferon only treatment (aHR = 0.32).
Béim ar na taighdeoirí gur mhol staidéar ag an gComhdháil Eorpach um Ghalar Ae anuraidh gur cosúil go bhfuil ráta atarlaithe níos airde d’ailse ae ag othair HCV a chóireáiltear le DAA. Tá an toradh seo an-chonspóideach, toisc go dtugann an gaol idir HCV agus ailse ae le fios gur cheart go laghdódh díothú HCV Níl an baol ailse ae chun an baol ailse ae a mhéadú. Tá conclúid an staidéir bhreathnaithe seo an-chinnte gur féidir le díothú DAA HCV an baol ailse ae a laghdú 71%, rud a thugann le tuiscint nach gá a bheith buartha faoi dhíothú HCV chun an baol ailse ae a mhéadú. Is éard atá i gceist le díothú HCV ná an baol ailse ae a laghdú.
